The Pro12Ala variant at the peroxisome proliferator-activated receptor γ gene and change in obesity-related traits in the Diabetes Prevention Program

Diabetologia

Volumn 50, Issue 12, 2007, Pages 2451-2460

  Franks, P W ^a,b,c   Jablonski, K A ^c   Delahanty, L ^d   Hanson, R L ^b   Kahn, S E ^e   Altshuler, D ^d,f   Knowler, W C ^b   Florez, J C ^d,f,g  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Computed tomography; Gene environment interaction; Obesity; Peroxisome proliferator activated receptor ; PPARG; PUFA intake; Randomised clinical trial; Subcutaneous fat; Visceral fat

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; LIPID BINDING PROTEIN; METFORMIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; POLYUNSATURATED FATTY ACID; PROLINE DERIVATIVE; TROGLITAZONE;

ADIPOGENESIS; ADIPOSE TISSUE; ADULT; ARTICLE; BODY COMPOSITION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIETARY INTAKE; DNA POLYMORPHISM; DRUG WITHDRAWAL; FEMALE; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEALTH CARE SYSTEM; HEALTH PROGRAM; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUBCUTANEOUS FAT; SUBSTITUTION REACTION; WEIGHT CHANGE; WEIGHT GAIN; WEIGHT REDUCTION;

ADULT; ALANINE; AMINO ACID SUBSTITUTION; BODY COMPOSITION; CHROMANS; DIABETES MELLITUS, TYPE 2; DIETARY FATS; EATING; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; LIFE STYLE; MALE; METFORMIN; MIDDLE AGED; OBESITY; PLACEBOS; PPAR GAMMA; PROLINE; THIAZOLIDINEDIONES;

EID: 35848936503     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-007-0826-6     Document Type: Article

References (39)

1. Despres JP (2006) Intra-abdominal obesity: an untreated risk factor for type 2 diabetes and cardiovascular disease. J Endocrinol Invest 29(3 Suppl):77-82
2. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195-1200
3. Wilson PW, D'Agostino RB, Sullivan L, Parise H, Kannel WB (2002) Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med 162:1867-1872
4. Huang Z, Hankinson SE, Colditz GA et al (1997) Dual effects of weight and weight gain on breast cancer risk. JAMA 278:1407-1411
5. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH (1999) The disease burden associated with overweight and obesity. JAMA 282:1523-1529
6. Fox CS, Heard-Costa NL, Vasan RS, Murabito JM, D'Agostino RB, Sr, Atwood LD (2005) Genomewide linkage analysis of weight change in the Framingham Heart Study. J Clin Endocrinol Metab 90:3197-3201
7. Franks PW, Ravussin E, Hanson RL et al (2005) Habitual physical activity in children: the role of genes and the environment. Am J Clin Nutr 82:901-908
8. James PT (2004) Obesity: the worldwide epidemic. Clin Dermatol 22:276-280
9. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM (2006) Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295:1549-1555
10. The Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403
11. Hamman RF, Wing RR, Edelstein SL et al (2006) Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care 29:2102-2107
12. Tonjes A, Scholz M, Loeffler M, Stumvoll M (2006) Association of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma with pre-diabetic phenotypes: meta-analysis of 57 studies on nondiabetic individuals. Diabetes Care 29:2489-2497
13. Yen CJ, Beamer BA, Negri C et al (1997) Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun 241:270-274
14. Deeb SS, Fajas L, Nemoto M et al (1998) A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20:284-287
15. Beamer BA, Yen CJ, Andersen RE et al (1998) Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes 47:1806-1808
16. Hansen L, Pedersen O (2005) Genetics of type 2 diabetes mellitus: status and perspectives. Diabetes Obes Metab 7:122-135
17. Florez JC, Jablonski KA, Sun MW et al (2007) Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone. J Clin Endocrinol Metab 92:1502-1509
18. The Diabetes Prevention Program Research Group (2000) The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 23:1619-1629
19. Block G, Subar AF (1992) Estimates of nutrient intake from a food frequency questionnaire: the 1987 National Health Interview Survey. J Am Diet Assoc 92:969-977
20. Mayer-Davis EJ, Sparks KC, Hirst K et al (2004) Dietary intake in the diabetes prevention program cohort: baseline and 1-year post randomization. Ann Epidemiol 14:763-772
21. Fujimoto WY, Jablonski KA, Bray GA et al (2007) Body size and shape changes and the risk of diabetes in the diabetes prevention program (DPP). Diabetes 56:1680-1685
22. Greenberg RS, Kleinbaum DG (1985) Mathematical modeling strategies for the analysis of epidemiologic research. Annu Rev Public Health 6:223-245
23. Holm S (1979) A simple sequentially rejective Bonferroni test procedure. Scand J Stat 6:5-70
24. Masud S, Ye S (2003) Effect of the peroxisome proliferator activated receptor-gamma gene Pro12Ala variant on body mass index: a meta-analysis. J Med Genet 40:773-780
25. Franks PW, Mesa JL, Harding AH, Wareham NJ (2007) Gene-lifestyle interaction on risk of type 2 diabetes. Nutr Metab Cardiovasc Dis 17:104-124
26. Lambe KG, Tugwood JD (1996) A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs. Eur J Biochem 239:1-7
27. Ferre P (2004) The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53 (Suppl 1):S43-S50
28. Barak WY, Nelson MC, Ong ES et al (1999) PPAR gamma is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585-595
29. Camp HS, Chaudhry A, Leff T (2001) A novel potent antagonist of peroxisome proliferator-activated receptor gamma blocks adipocyte differentiation but does not revert the phenotype of terminally differentiated adipocytes. Endocrinology 142:3207-3213
30. Ebbesson SO, Risica PM, Ebbesson LO, Kennish JM, Tejero ME (2005) Omega-3 fatty acids improve glucose tolerance and components of the metabolic syndrome in Alaskan Eskimos: the Alaska Siberia project. Int J Circumpolar Health 64:396-408
31. Franks PW, Luan J, Browne PO et al (2004) Does peroxisome proliferator-activated receptor gamma genotype (Pro12ala) modify the association of physical activity and dietary fat with fasting insulin level? Metabolism 53:11-16
32. Luan J, Browne PO, Harding AH et al (2001) Evidence for gene-nutrient interaction at the PPARgamma locus. Diabetes 50:686-689
33. Memisoglu A, Hu FB, Hankinson SE et al (2003) Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass. Hum Mol Genet 12:2923-2929
34. Robitaille J, Despres JP, Perusse L, Vohl MC (2003) The PPAR-gamma P12A polymorphism modulates the relationship between dietary fat intake and components of the metabolic syndrome: results from the Quebec Family Study. Clin Genet 63:109-116
35. Altshuler D, Hirschhorn JN, Klannemark M et al (2000) The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 26:76-80
36. Lindi VI, Uusitupa MI, Lindstrom J et al (2002) Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51:2581-2586
37. Poirier O, Nicaud V, Cambien F, Tiret L (2000) The Pro12Ala polymorphism in the peroxisome proliferator-activated receptor gamma2 gene is not associated with postprandial responses to glucose or fat tolerance tests in young healthy subjects: the European Atherosclerosis Research Study II. J Mol Med 78:346-351
38. Kim KS, Choi SM, Shin SU, Yang HS, Yoon Y (2004) Effects of peroxisome proliferator-activated receptor-gamma 2 Pro12Ala polymorphism on body fat distribution in female Korean subjects. Metabolism 53:1538-1543
39. Heitmann BL, Lissner L (2005) Can adverse effects of dietary fat intake be overestimated as a consequence of dietary fat underreporting? Public Health Nutr 8:1322-1327